Suppr超能文献

一家儿科医院中对非甾体抗炎药、COX-2抑制剂和扑热息痛的药物不良反应

Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital.

作者信息

Titchen Thirza, Cranswick Noel, Beggs Sean

机构信息

Royal Children's Hospital, Parkville, Australia.

出版信息

Br J Clin Pharmacol. 2005 Jun;59(6):718-23. doi: 10.1111/j.1365-2125.2005.02444.x.

Abstract

AIMS

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in children has rapidly escalated over the last 5 years in Australia. This is primarily as a result of the availability of ibuprofen as an over-the-counter preparation. Several recent, significant adverse drug reactions (ADRs) to NSAIDs, at the Royal Children's Hospital (RCH) in Melbourne, Australia prompted review of all of the RCH reactions reported to these agents over 5 years.

METHODS

The ADR programme documents both spontaneously reported ADRs and ADRs identified by discharge coding. For this study, reported reactions to aspirin, celecoxib, ibuprofen, indomethacin, naproxen, paracetamol and rofecoxib, for the previous 5-year period, were retrieved from the hospital ADR database.

RESULTS

Nineteen reports of ADRs to NSAIDs and six to paracetamol, in patients aged from 4 months to 22 years (median 10 years) were identified. Reactions were predominantly rash (n = 10), gastrointestinal (n = 5) and respiratory (n = 4) side-effects. These included reports of haematemesis with both celecoxib and ibuprofen. One patient died of severe acute exacerbation of asthma following initiation of rofecoxib.

CONCLUSION

NSAID exposures are a significant cause of morbidity in children. Both nonselective NSAIDs and the newer COX-2 inhibitors were associated with significant drug reactions. The overall severity of these ADRs highlights the need for vigilant surveillance of ADRs in paediatrics, including both established and newer agents.

摘要

目的

在过去5年中,澳大利亚儿童使用非甾体抗炎药(NSAIDs)的情况迅速增加。这主要是由于布洛芬可作为非处方药获得。澳大利亚墨尔本皇家儿童医院(RCH)近期发生了几起严重的NSAIDs药物不良反应(ADR),促使对过去5年向这些药物报告的所有RCH不良反应进行审查。

方法

ADR项目记录了自发报告的ADR和通过出院编码确定的ADR。在本研究中,从医院ADR数据库中检索了过去5年报告的对阿司匹林、塞来昔布、布洛芬、吲哚美辛、萘普生、对乙酰氨基酚和罗非昔布的反应。

结果

确定了19例NSAIDs的ADR报告和6例对乙酰氨基酚的ADR报告,患者年龄从4个月至22岁(中位数10岁)。反应主要为皮疹(n = 10)、胃肠道(n = 5)和呼吸道(n = 4)副作用。其中包括塞来昔布和布洛芬导致呕血的报告。1例患者在开始使用罗非昔布后死于哮喘严重急性加重。

结论

NSAIDs暴露是儿童发病的重要原因。非选择性NSAIDs和新型COX-2抑制剂均与严重药物反应相关。这些ADR的总体严重性凸显了对儿科ADR进行警惕监测的必要性,包括已有的和新型药物。

相似文献

引用本文的文献

本文引用的文献

3
Acute renal failure after treatment with non-steroidal anti-inflammatory drugs.非甾体抗炎药治疗后出现的急性肾衰竭
Eur J Pediatr. 2004 Mar;163(3):148-50. doi: 10.1007/s00431-003-1392-7. Epub 2004 Jan 24.
6
Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma.阿司匹林敏感性哮喘中的环氧化酶-2抑制剂
Chest. 2003 Jun;123(6):2155-6; author reply 2156. doi: 10.1378/chest.123.6.2155.
10
Aseptic meningitis associated with rofecoxib.与罗非昔布相关的无菌性脑膜炎。
Arch Intern Med. 2002 Mar 25;162(6):713-5. doi: 10.1001/archinte.162.6.713.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验